Education
About Us
Working with TipRanks
Follow Us
Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Total Valuation
Bafna Pharmaceuticals Limited has a market cap or net worth of ₹1.75B. The enterprise value is ₹2.13B.
Market Cap₹1.75B
Enterprise Value₹2.13B
Share Statistics
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,656,336
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bafna Pharmaceuticals Limited’s return on equity (ROE) is 0.05 and return on invested capital (ROIC) is 5.45%.
Return on Equity (ROE)0.05
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)5.45%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.95
Inventory Turnover4.59
Valuation Ratios
The current PE Ratio of Bafna Pharmaceuticals Limited is 0.00. Bafna Pharmaceuticals Limited’s PEG ratio is -0.74.
PE Ratio0.00
PS Ratio0.00
PB Ratio2.35
Price to Fair Value0.00
Price to FCF-29.80
Price to Operating Cash Flow19.99
PEG Ratio-0.74
Income Statement
In the last 12 months, Bafna Pharmaceuticals Limited had revenue of 1.46B and earned 41.52M in profits. Earnings per share was 1.76.
Revenue1.46B
Gross Profit168.77M
Operating Income62.87M
Pretax Income41.52M
Net Income41.52M
EBITDA117.73M
Earnings Per Share (EPS)1.76
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Bafna Pharmaceuticals Limited pays an annual dividend of ₹0.6, resulting in a dividend yield of ―
Dividend Per Share₹0.6
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.36
52-Week Price Change-0.09%
50-Day Moving Average75.06
200-Day Moving Average78.62
Relative Strength Index (RSI)47.34
Average Volume (3m)1.33K
Important Dates
Bafna Pharmaceuticals Limited upcoming earnings date is Aug 8, 2025, TBA (Confirmed).
Last Earnings DateMay 26, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend DateSep 19, 2013
Financial Position
Bafna Pharmaceuticals Limited as a current ratio of 1.63, with Debt / Equity ratio of 30.17%
Current Ratio1.63
Quick Ratio1.09
Debt to Market Cap0.00
Net Debt to EBITDA2.10
Interest Coverage Ratio2.30
Taxes
In the past 12 months, Bafna Pharmaceuticals Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Bafna Pharmaceuticals Limited EV to EBITDA ratio is 2.10, with an EV/FCF ratio of -10.63.
EV to Sales0.17
EV to EBITDA2.10
EV to Free Cash Flow-10.63
EV to Operating Cash Flow1.27
Balance Sheet
Bafna Pharmaceuticals Limited has ₹13.15M in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹13.15M billion.
Cash & Marketable Securities₹13.15M
Total Debt₹0.00
Net Cash-₹13.15M
Net Cash Per Share-₹0.56
Tangible Book Value Per Share₹0.00
Margins
Gross margin is 29.66%, with operating margin of 4.31%, and net profit margin of 2.85%.
Gross Margin29.66%
Operating Margin4.31%
Pretax Margin2.85%
Net Profit Margin2.85%
EBITDA Margin8.07%
EBIT Margin4.72%
Analyst Forecast
The average price target for Bafna Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―